Miriam E. Tucker

Initial real-world results of patients receiving paltusotine suggest reduced symptoms and good tolerability, while a phase 3 trial finds no interaction with levothyroxine.

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have resulted in a flood of new treatments.

Guidelines advise slow serum sodium correction to avoid osmotic demyelination, but recent data suggest that risk is low, and rapid correction may produce better outcomes.

The urine albumin/creatinine ratio time in target range predicts cardiovascular outcomes in people with and without chronic kidney disease.

May 18, 2026 The FDA has approved a dosing update for burosumab -twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH).

A large database study shows lower risk for major adverse cardiovascular events and end-stage kidney disease, with no increase in adverse events.

A survey found that clinicians are not discussing genetic testing with 80% of patients with kidney disease who meet established clinical criteria.

New receptor agonist combinations, a once-monthly GLP-1, and full retatrutide data are all on the agenda, along with a huge spectrum of other diabetes-related content.

The FDA first approved MannKind’s Afrezza for adults with diabetes in 2014.